On behalf of an established Alacrita client, a publicly traded clinical stage biotechnology company with a cell therapy platform technology, we assessed the potential of a novel extracellular vesicle technology across a range of potential applications. The technology, which had been developed in-house, was based on vesicles produced from stem cells. The client asked Alacrita to assess the competitiveness of its technology and, if appropriate, to develop a strategy based on selected applications/disease indications.
Alacrita assembled a multidisciplinary team to conduct a phased work-plan involving:
We can help you gauge and rank the opportunities for your R&D programs or technology platforms to deliver value, by framing the commercial potential and charting the path to market.